This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Roche Holding 경영진
경영진 기준 점검 2/4
현재 CEO에 대한 정보가 충분하지 않습니다.
핵심 정보
Thomas Schinecker
최고경영자
n/a
총 보수
| CEO 급여 비율 | n/a |
| CEO 재임 기간 | 3yrs |
| CEO 지분 보유율 | 0.0004% |
| 경영진 평균 재임 기간 | 6yrs |
| 이사회 평균 재임 기간 | 6yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Mar 21
ROG: 2026 Clinical Catalysts And Obesity Data Will Drive Upside Potential
Analysts now place fair value for Roche Holding at CHF 363.47. This is a modest adjustment supported by mixed recent research that highlights softer revenue growth and profit margin assumptions, a higher future P/E, and a wider spread of Street price targets ranging from CHF 325 to CHF 390, alongside ratings that span from Neutral to Buy.
내러티브 업데이트 • Mar 07
ROG: Genomics Pricing And Cautious Pipeline Outlook Will Constrain Future Upside
The analyst fair value estimate for Roche Holding has been raised from CHF 230.00 to CHF 262.39, as analysts factor in updated assumptions for revenue growth, profit margins, and a lower future P/E multiple, alongside recent Street price target increases and more constructive views on the pipeline and diagnostics pricing. Analyst Commentary Recent research has highlighted a mixed but generally more constructive tone around Roche, with fresh attention on pricing decisions, the pipeline, and relative positioning versus peers in diagnostics and genomics.내러티브 업데이트 • Feb 21
ROG: Pipeline Milestones And Digital Execution Will Shape Balanced Risk Reward Ahead
Roche Holding's updated analyst price target has moved higher to reflect a fair value shift to CHF 358.45 from CHF 323.28. Analysts point to improved growth and margin assumptions, alongside recent upgrades and higher CHF-based targets from several banks.
내러티브 업데이트 • Feb 07
ROG: 2026 Clinical Pipeline And Execution Progress Will Drive Future Rerating
Analysts have nudged their fair value estimate for Roche Holding slightly higher to CHF 428, citing a mix of updated assumptions around revenue growth, profit margins, discount rates and future P/E multiples, along with recent upward moves in Street price targets and more constructive research coverage. Analyst Commentary Bullish analysts have become more constructive on Roche in recent months, with several research notes pointing to upgraded ratings, refreshed price targets and improving sentiment around the pipeline and execution.분석 기사 • Feb 03
Roche Holding AG (VTX:ROG) Annual Results: Here's What Analysts Are Forecasting For This Year
As you might know, Roche Holding AG ( VTX:ROG ) recently reported its annual numbers. It was a pretty mixed result...
새로운 내러티브 • Feb 01
Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond
About Roche Holding AG Roche is one of the world’s largest pharmaceutical companies, with a market capitalization of approximately CHF 300 billion (USD 380bn). The company operates through two primary divisions: •Roche Pharmaceuticals: A global leader in biotechnology and the leading provider of treatments for cancer.내러티브 업데이트 • Jan 23
ROG: 2026 Clinical Milestones And Execution Progress Will Drive Future Rerating
Analysts have raised their price expectations for Roche Holding, citing updated assumptions that include improved revenue growth, a slightly lower projected profit margin, and a modestly reduced future P/E multiple. These changes are supported by recent rating upgrades and positive commentary on clinical catalysts and the operational outlook.내러티브 업데이트 • Jan 09
ROG: 2026 Clinical Readouts Will Shape Sentiment On Pipeline Execution
Analysts have lifted their fair value estimate for Roche Holding from CHF 400.07 to CHF 427.00, citing recent upgrades, clinical readouts and what they see as an undemanding valuation, which they believe is supported by 2026 clinical catalysts and ongoing program progress. Analyst Commentary Recent Street research around Roche highlights a cluster of positive opinions that center on clinical execution, program progress and what some see as a valuation that does not fully reflect these factors.내러티브 업데이트 • Dec 17
ROG: Pipeline Data And Digital Execution Will Shape Balanced Risk Reward Ahead
Analysts have nudged their fair value estimate for Roche Holding higher, lifting the target by about CHF 11.50 to reflect slightly stronger long term revenue growth and margin assumptions supported by recent positive readthroughs from partners, incremental pipeline visibility, and a modest firming in Street price targets. Analyst Commentary Bullish analysts emphasize that recent partner updates and pipeline milestones are incrementally improving sentiment on Roche, supporting the view that medium term growth and margin visibility are strengthening despite a still mixed backdrop.내러티브 업데이트 • Dec 03
ROG: Pipeline Readouts And Commercial Execution Will Shape Balanced Risk Reward Ahead
Analysts modestly raise their price target on Roche Holding, reflecting an updated fair value estimate of approximately CHF 312 from about CHF 305 as they factor in slightly stronger long term revenue growth, improving margins, and supportive readthroughs from recent pipeline and partnership developments. Analyst Commentary Recent Street commentary around Roche continues to frame the company as a strategically important player in oncology, ophthalmology, and digital enablement, while also highlighting competitive and execution risks that temper upside expectations.내러티브 업데이트 • Nov 19
ROG: Sector Pressures And Mixed Trial Results Will Shape Performance Ahead
Roche Holding’s analyst price target has been raised by CHF 10 to CHF 255. Analysts cite moderate adjustments to fair value estimates, along with continued caution regarding recent trial outcomes and sector dynamics.분석 기사 • Aug 20
Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)
SWX:ROG 1 Year Share Price vs Fair Value Explore Roche Holding's Fair Values from the Community and select yours With a...새로운 내러티브 • Feb 04
Roche Holding will see a 4.2576% revenue growth shaking the market
### **Analyse der Roche Jahreszahlen 2024: Wachstum setzt sich fort, Herausforderungen bleiben_20250130 #### Zusammenfassung der ErgebnisseRoche hat für das Jahr 2024 ein solides Wachstum von 7 % auf
새로운 내러티브 • Feb 02
Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025
Successful Pharma pipeline and innovative diagnostics launches are anticipated to drive long-term revenue growth and operating profit.CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | CHF 13b |
| Sep 30 2025 | n/a | n/a | CHF 11b |
| Jun 30 2025 | n/a | n/a | CHF 9b |
| Mar 31 2025 | n/a | n/a | CHF 9b |
| Dec 31 2024 | n/a | n/a | CHF 8b |
| Sep 30 2024 | n/a | n/a | CHF 9b |
| Jun 30 2024 | n/a | n/a | CHF 11b |
| Mar 31 2024 | n/a | n/a | CHF 11b |
| Dec 31 2023 | n/a | n/a | CHF 11b |
| Sep 30 2023 | n/a | n/a | CHF 11b |
| Jun 30 2023 | n/a | n/a | CHF 11b |
| Mar 31 2023 | n/a | n/a | CHF 12b |
| Dec 31 2022 | CHF 5m | CHF 1m | CHF 12b |
| Sep 30 2022 | n/a | n/a | CHF 14b |
| Jun 30 2022 | n/a | n/a | CHF 15b |
| Mar 31 2022 | n/a | n/a | CHF 14b |
| Dec 31 2021 | CHF 4m | CHF 1m | CHF 14b |
| Sep 30 2021 | n/a | n/a | CHF 14b |
| Jun 30 2021 | n/a | n/a | CHF 14b |
| Mar 31 2021 | n/a | n/a | CHF 14b |
| Dec 31 2020 | CHF 4m | CHF 879k | CHF 14b |
| Sep 30 2020 | n/a | n/a | CHF 14b |
| Jun 30 2020 | n/a | n/a | CHF 13b |
| Mar 31 2020 | n/a | n/a | CHF 13b |
| Dec 31 2019 | CHF 2m | CHF 609k | CHF 13b |
보상 대 시장: Swiss 시장에서 비슷한 규모 기업과 비교해 Thomas의 총 보수가 적절한지 판단하기에 데이터가 부족합니다.
보상과 수익: Thomas의 보상은 지난 1년 동안 20% 이상 증가했습니다.
CEO
Thomas Schinecker (50 yo)
3yrs
재임 기간
CHF 5,335,592
보수
Dr. Thomas Schinecker is Chairman of the Board of Roche Holdings, Inc. from March 14, 2023. Dr. Schinecker is Director since March 27, 2025 at Chugai Pharmaceutical Co., Ltd. He serves as Chairman of the B...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Executive Chairman | 13yrs | CHF 11.48m | 0.045% CHF 115.3m | |
| Group Chief Executive Officer | 3yrs | CHF 5.34m | 0.00045% CHF 1.2m | |
| Chief Financial Officer | 14.9yrs | CHF 6.05m | 0.0066% CHF 17.1m | |
| Head of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| General Counsel | 5.9yrs | 데이터 없음 | 데이터 없음 | |
| Chief Compliance Officer | 6.2yrs | 데이터 없음 | 데이터 없음 | |
| Head of Group Communications | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief People Officer | 10yrs | CHF 4.25m | 0.0022% CHF 5.6m | |
| Head of Group Media Relations | no data | 데이터 없음 | 데이터 없음 | |
| Head of Corporate Business Development | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Immunology | no data | 데이터 없음 | 데이터 없음 | |
| Global Head of Ophthalmology Roche pRED | no data | 데이터 없음 | 데이터 없음 |
6.0yrs
평균 재임 기간
55.5yo
평균 나이
경험이 풍부한 관리: ROG의 경영진은 노련하고 경험이 풍부합니다(평균 재임 6 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Executive Chairman | 13yrs | CHF 11.48m | 0.045% CHF 115.3m | |
| Director | 3yrs | 데이터 없음 | 0.00063% CHF 1.6m | |
| Independent Vice Chairman | 30.2yrs | CHF 400.00k | 3.54% CHF 9.1b | |
| Independent Non Executive Director | 6yrs | CHF 360.00k | 0.00050% CHF 1.3m | |
| Non-Executive Independent Director | 11.2yrs | CHF 346.71k | 0% CHF 0 | |
| Non-Executive Independent Director | 9yrs | CHF 336.16k | 0.00059% CHF 1.5m | |
| Director | no data | 데이터 없음 | 데이터 없음 | |
| Non-Executive Independent Director | 6yrs | CHF 394.67k | 데이터 없음 | |
| Director | 3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 4yrs | CHF 272.50k | 데이터 없음 |
6.0yrs
평균 재임 기간
57.5yo
평균 나이
경험이 풍부한 이사회: ROG의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/03/16 07:54 |
| 종가 | 2026/03/16 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Roche Holding AG는 44명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| John Staszak | Argus Research Company |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Mark Purcell | Barclays |